{"id":4003,"date":"2025-03-31T18:11:55","date_gmt":"2025-03-31T18:11:55","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/fluphenazine-txt\/"},"modified":"2025-03-31T18:11:55","modified_gmt":"2025-03-31T18:11:55","slug":"fluphenazine-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/fluphenazine-txt\/","title":{"rendered":"Fluphenazine.txt"},"content":{"rendered":"

Fluphenazine <\/h1>\n

CLINICAL USE <\/H3>
\nAntipsychotic:Mania, schizophrenia and other psychoses Short-term use for anxiety, psychomotor agitation, excitement and violent or dangerously impulsive behaviour

DOSE IN NORMAL RENAL FUNCTION <\/H3>Oral:Mania, schizophrenia and other psychoses: 2\u201320 mg daily in 2\u20133 divided dosesShort-term use for anxiety, psychomotor agitation, excitement and violent or dangerously impulsive behaviour: 1\u20132 mg twice dailyDeep IM:Schizophrenia and other psychoses: 12.5\u2013 100 mg every 14\u201335 days

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :437.5, 510.4 (as hydrochloride), (591.8 as decanoate)<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :>90 <\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 20<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :10<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :14.7 (6\u20139 days after IM)

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Start with a low dose and titrate slowly

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in GFR <10 mL\/min <\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Anaesthetics: enhanced hypotensive effect\n
  • Analgesics: increased risk of convulsions with tramadol; enhanced hypotensive and sedative effects with opioids\n
  • Anti-arrhythmics: increased risk of ventricular arrhythmias with anti-arrhythmics that prolong the QT interval; avoid concomitant use with amiodarone\n
  • Antibacterials: increased risk of ventricular arrhythmias with moxifloxacin \u2013 avoid concomitant use\n
  • Antidepressants: increased plasma level of tricyclics; possibly increased risk of ventricular arrhythmias and antimuscarinic side effectsAnticonvulsant: antagonises anticonvulsant effect\n
  • Antimalarials: avoid concomitant use with artemether\/lumefantrine\n
  • Antipsychotics: increased risk of ventricular arrhythmias with pimozide \u2013 avoid concomitant use; avoid concomitant use of depot formulations with clozapine (cannot be withdrawn quickly if neutropenia occurs)\n
  • Antivirals: concentration possibly increased with ritonavirAnxiolytics and hypnotics: increased sedative effects\n
  • Beta-blockers: enhanced hypotensive effect; increased risk of ventricular arrhythmias with sotalol\n
  • Diuretics: enhanced hypotensive effect\n
  • Lithium: increased risk of extrapyramidal side effects and possibly neurotoxicity\n
  • Pentamidine: increased risk of ventricular arrhythmias\n
  • Sibutramine: increased risk of CNS toxicity \u2013 avoid concomitant useAvoid concomitant use with drugs that prolong the QT interval

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral, IM

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>
    \n","protected":false},"excerpt":{"rendered":"

    Fluphenazine CLINICAL USE Antipsychotic:Mania, schizophrenia and other psychoses Short-term use<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4003","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4003","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4003"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4003\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4003"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4003"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4003"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}